Clinical trial SAFFRON
A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2021-006374-24 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05261399 |
| Last update |